- Drug Pipelines
- January 2022
- 30 Pages
Global
From €454EUR$500USD£389GBP
Exjade (deferasirox) is a cardiovascular drug used to treat iron overload caused by blood transfusions. It is an oral medication that works by binding to iron in the body and helping to remove it through the urine. Exjade is approved for use in adults and children over two years of age. It is also used to reduce the risk of organ damage caused by iron overload.
Exjade is marketed by Novartis, a Swiss multinational pharmaceutical company. The drug is available in tablet and oral suspension forms. It is also available in generic forms from other manufacturers.
In the Exjade market, some of the major players include Novartis, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Other companies in the market include Dr. Reddy's Laboratories, Aurobindo Pharma, and Glenmark Pharmaceuticals. Show Less Read more